98%
921
2 minutes
20
In France, patients' claim for information and participation to medical decision-making was initiated in the eighties by AIDS associations, then reinforced by the tainted blood scandal and more recently by demands from cancer patients. The right to patient information was recognised on March 4th 2002 by the law pertaining to patients' rights and the quality of the healthcare system. The present article will explore this background by examining the bases, the current status and the development of shared decision-making in the physician-patient encounter in France. We will describe the evolution of the physician-patient relationship on the basis of legal and administrative documents, then show that patients' information, and more generally healthcare users' information, is a central concern for some national health institutions. Finally, we will demonstrate that even if the literature on shared decision-making is little developed in France as compared to other European countries, Northern America and Australia, some studies have nonetheless been conducted. Their results, combined with a legal context and national health institutions encouraging shared decision-making, should prompt otherwise reluctant healthcare professionals to implement this approach in everyday medical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.zgesun.2007.02.042 | DOI Listing |
Cereb Cortex
August 2025
Brain and Cognition, KU Leuven, Tiensestraat 102, 3000 Leuven, Belgium.
Centro-parietal electroencephalogram signals (centro-parietal positivity and error positivity) correlate with the reported level of confidence. According to recent computational work these signals reflect evidence which feeds into the computation of confidence, not directly confidence. To test this prediction, we causally manipulated prior beliefs to selectively affect confidence, while leaving objective task performance unaffected.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock.
Importance: Patients with kidney failure (KF) receiving long-term dialysis have increased incidence of atrial fibrillation (AF). Patients with KF and AF have increased risk of stroke, death, and bleeding compared with age-matched cohorts. In KF, the use of oral anticoagulants (OACs) increases hemorrhage risk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promising solution for risk reduction in AF.
View Article and Find Full Text PDFCurr Atheroscler Rep
September 2025
Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, 521 19th Street South-GSB 444, Birmingham, AL, 35233, USA.
Purpose Of Review: This review examines cardiovascular disease (CVD) risk prediction models relevant to older adults, a rapidly expanding population with elevated CVD risk. It discusses model characteristics, performance metrics, and clinical implications.
Recent Findings: Some models have been developed specifically for older adults, while several others consider a broader age range, including some older individuals.
Community Ment Health J
September 2025
Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, 10027, USA.
Guided by the Ottawa Decision Support Framework, we created a depression care decision aid for Latinx and African American individuals with major depressive disorder (MDD) at a network of Federally Qualified Health Centers. We surveyed 94 African American and Latinx individuals with MDD about their decision making needs. Focus groups elaborated on these preferences.
View Article and Find Full Text PDFInt J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDF